In a randomised trial of 59 patients with major depressive disorder, psilocybin (COMP360) but not escitalopram produced significant reductions in rumination and thought suppression over 6 weeks; decreased thought suppression was specific to psilocybin responders while rumination fell in responders to both treatments. Reductions in both measures in the psilocybin arm correlated with ego dissolution and session-linked psychological insight, suggesting these processes may mediate its antidepressant effects.
- Published
- Journal
- BJPsych Open
- Authors
- Barba, T., Buehler, S., Kettner, H., Radu, C., Cunha, G., Nutt, D. J., Erritzoe, D., Roseman, L., Carhart-Harris, R. L.